A Busy Week for Multiple Sclerosis News
It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.
988
Encouraging Fragile X Data for Seaside Therapeutics
Seaside Therapeutics reported encouraging results from the largest randomized study conducted to date in patients with Fragile X syndrome.
[Company Profile] Altea Therapeutics
One of the more impressive companies at the IN3 West conference was Altea Therapeutics, an Atlanta-based clinical stage company involved in drug delivery.
FDA to Collaborate with Pharma Companies on New TB Initiative
A number of pharmaceutical companies will collaborate with FDA scientists to test new TB combination therapies and identify promising candidates.
Pressure BioSciences Aims for Improved Sample Preparation
Pressure BioSciences seeks to improve sample yield with its novel technology platform, known as pressure cycling technology (PCT).
Nasdaq Buoyed by Biotech
The Nasdaq rose 5 points on Monday, due in part to recent happenings in the biopharmaceutical sector.
First Swine Flu Vaccines Approved
The U.S. government has approved swine flu vaccines from four pharmaceutical companies, Reuters reports.
Opexa Shares Soar on Multiple Sclerosis Trial Data
Opexa Therapeutics announced that 83 percent of clinical trial patients taking its therapeutic vaccine Tovaxin remained relapse-free for a year.